Exhibit 99.1

 

 

 

BIONIK Laboratories Announces Fiscal 2021 Q1 Financial Results

 

TORONTO & BOSTON – August 13, 2020 -- BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for its first quarter of fiscal year 2021, ended June 30, 2020.

 

Financial highlights for the first quarter of fiscal year 2021 ended June 30, 2020 and recent weeks include:

 

·During the COVID-19 pandemic, BIONIK managed to ship InMotion™robots to customers in the United States.

 

·Gross margin for the quarter ended June 30, 2020 was $195,353, or 75.7%, due to a reversal of an overstated warranty reserve (57.6% without the effects of the warranty adjustment), compared to $454,294 or 57.5% for the quarter ended June 30, 2019.

 

·Raised approximately $1,502,569 during the fiscal quarter ended June 30, 2020 and in early July, 2020.

 

Corporate highlights for the first quarter of fiscal year 2021 ended June 30, 2020 and recent weeks include:

 

·On June 25, 2020, launched InMotion Connect™, a cloud-based data analytics solution, which combines real-time robot data with deep expertise of BIONIK’s clinical specialists to partner with each clinic, promoting robot utilization, supporting clinician engagement, and enhancing patient care by providing contextual and relevant data to reach hospital clinicians and management teams when it matters the most.

 

·Donated InMotion® Robotic System to Einstein Healthcare Network’s MossRehab for Use in New COVID-19 Rehab Unit.

 

Management Commentary

 

Commenting on the quarter, Dr. Eric Dusseux, BIONIK’s Chief Executive Officer, said, " With the COVID-19 pandemic, we are in a time of our lives and one within society that we have never experienced before. It is truly unprecedented, which is why BIONIK is operating under a modified plan to reduce costs and otherwise address the effects on our business caused by COVID-19. We sold InMotion™robots to customers in the U.S. We were extremely proud to donate an InMotion® robot to MossRehab, and to help patients inflicted with COVID-19 get the critical therapy they need as they seek a return toward a normal life within their communities, and support their dedicated healthcare team with their tireless efforts to rehabilitate patients. We launched InMotion Connect™ targeting the critical need to improve technology adoption at each rehabilitation clinic that can be monitored through the platform to ensure that the state-of-the-art rehabilitation methods are effectively in use across the hospital network. The single platform, already deployed in one Kindred site, that can be accessed anywhere, anytime, helps increasing technology adoption due to convenience and ease-of-use for the clinician, hospital management and headquarter teams.”

 

 

 

 

BIONIK continues to expect to achieve the following milestones during fiscal year 2021:

 

·Continue to expand sales channels in North America and abroad.

 

·Further develop InMotion Connect solutions to serve clinical rehabilitation providers.

 

·Work with our commercial outsourced manufacturing partner to enhance effectiveness in order to support the expected increase in product demand and introduction of new products.

 

·Increase sales of data solutions, service contracts and warranties.

 

Financial Results

 

Sales for the quarter ended June 30, 2020 were $257,908, compared with $790,379 for the quarter ended June 30, 20119. The decrease reflects the sale of two InMotion™robots sold during the COVID-19 pandemic compared to eight InMotion™ robots in the quarter end June 30, 2019. In addition, deferred revenue, comprised of training to be provided and extended warranties, decreased to $582,281 at June 30, 2020 from $616,063 at March 31, 2020. The Company believes that extended warranties and training are important and growing parts of its business.

 

Gross margin for the quarter ended June 30, 2020 was $195,353, or 75.7%, due to a reversal of an overstated warranty reserve (57.6% without the effects of the warranty adjustment), compared to $454,294 or 57.5% for the quarter ended June 30, 2019.

 

The Company reported a comprehensive loss for the quarter ended June 30, 2020 of $(2,007,076), or a loss per share of $(0.39), compared with a comprehensive loss of $(2,120,644), or a loss per share of $(0.55), for the quarter ended June 30, 2019.

 

BIONIK had cash and cash equivalents of $2,403,037 as of June 30, 2020, compared to $2,269,747 as of March 31, 2020. The Company’s working capital deficit at June 30, 2020 was $931,222 compared to a working capital surplus of $626,923 as of March 31, 2020. The working capital deficit at June 30, 2019 is due to convertible loans received by the Company during the quarter being recorded as current liabilities rather than in equity when the loans are converted.

 

About BIONIK Laboratories Corp.

 

BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development.

 

For more information, please visit www.BIONIKlabs.com and connect with us on Twitter, LinkedIn, and Facebook.

 

Forward-Looking Statements

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of robotic rehabilitation products and other Company products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the impact on the Company’s business as a result of the Covid-19 pandemic, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

 

Media contact:

 

Matthew Bretzius
FischTank PR
matt@fischtankpr.com

 

 

 

 

Bionik Laboratories Corp.

Condensed Consolidated Interim Balance Sheets (unaudited)

(Amounts expressed in US Dollars)

 

   As at   As at 
   June 30,
2020
   March 31,
2020
 
   $   $ 
       (Audited) 
Assets          
Current          
Cash and cash equivalents   2,403,037    2,269,747 
Accounts receivable, net of allowance for doubtful accounts of $Nil (March 31, 2020 - $167,500)   975,272    846,964 
Prepaid expenses and other receivables (   1,723,353    1,632,555 
Inventories   944,990    1,059,462 
Due from related parties   18,657    17,840 
Total Current Assets   6,065,309    5,826,568 
Equipment   136,032    154,144 
Technology and other assets   1,426,420    1,449,924 
Goodwill   11,085,984    11,085,984 
Total Assets   18,713,745    18,516,620 
Liabilities and Shareholders' Equity          
Current          
Accounts Payable   443,874    857,093 
Accrued liabilities   2,057,784    1,647,656 
PPP Loan   459,912    - 
Convertible Loans   3,452,680    2,078,833 
Deferred revenue - Contract Liabilities   582,281    616,063 
Total Current Liabilities   6,996,531    5,199,645 
Shareholders' Equity          
Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2020 – 1)   -    - 
Common Shares, par value $0.001; Authorized - 500,000,000; Issued and outstanding 5,009,151 and 117,683 Exchangeable Shares (March 31, 2020 5,009,151 and 117,683 Exchangeable Shares)   5,126    5,126 
Additional paid in capital   85,050,885    84,643,570 
Deficit   (73,380,946)   (71,373,870)
Accumulated other comprehensive income   42,149    42,149 
Total Shareholders' Equity   11,717,214    13,316,975 
Total Liabilities and Shareholders' Equity   18,713,745    18,516,620 

  

 

 

  

Bionik Laboratories Corp.

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

For the three month periods ended June 30, 2020 and 2019 (unaudited)

(Amounts expressed in U.S. Dollars)

 

  

Three months

ended

  

Three months

ended

 
   June 30, 2020   June 30, 2019 
   $   $ 
Sales   257,908    790,379 
Cost of Sales   62,555    336,085 
Gross Margin   195,353    454,294 
Operating expenses          
Sales and marketing   223,185    583,732 
Research and development   353,263    816,523 
General and administrative   1,128,510    841,693 
Share-based compensation expense   407,315    287,757 
Amortization   23,504    69,314 
Depreciation   18,112    23,970 
Total operating expenses   2,153,889    2,622,989 
Other (income) expenses          
Other expense   74,975    14,296 
Other income   (37,612)   - 
Foreign exchange   11,177    (62,347)
Total other income (expenses)   48,540    (48,051)
Net loss and comprehensive loss for the period   (2,007,076)   (2,120,644)
Loss per share - basic and diluted   (0.39)   (0.55)
Weighted average number of shares outstanding – basic and diluted   5,126,834    3,858,637 

 

 

 

 

Condensed Consolidated Interim Statements of Cash Flows 

For the three month periods ended June 30, 2020 and 2019 (unaudited)

(Amounts expressed in U.S. Dollars)

 

  

Three months

ended

  

Three months

ended

 
  

June 30, 2020

$

  

June 30, 2019

$

 
Operating activities          
Net loss for the period   (2,007,076)   (2,120,644)
Adjustment for items not affecting cash          
Depreciation   18,112    23,970 
Amortization   23,504    69,314 
Interest expense   74,975    13,283 
Share based compensation expense   407,315    287,757 
    (1,483,170)   (1,726,320)
Changes in non-cash working capital items          
Accounts receivable   (128,308)   496,181 
Prepaid expenses and other receivables   (90,798)   160,305 
Due from related parties   (817)   (483)
Inventories   114,472    (176,376)
Accounts payable   (413,219)   (93,835)
Accrued liabilities   406,425    (41,434)
Deferred revenue   (33,782)   58,016 
Net cash (used in) operating activities   (1,629,197)   (1,323,946)
Investing activities          
Acquisition of equipment   -    (42,802)
Net cash (used in) investing activities   -    (42,802)
Financing activities          
Proceeds from convertible loans   1,302,575    950,000 
Proceeds from PPP Loan   459,912    - 
Proceeds from term loan   -    500,000 
Net cash provided by financing activities   1,762,487    1,450,000 
Net increase in cash and cash equivalents for the period   133,290    83,252 
Cash and cash equivalents, beginning of the period   2,269,747    446,779 
Cash and cash equivalents, end of the period   2,403,037    530,031